Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
weekdays
infrequent
weekly
infrequent
every other week
monthly
every other week
monthly
infrequent
Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis. CME information and select publications here.
Clinical investigators discuss available data guiding the management of multiple myeloma. CME information and select publications here.
Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.
Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma. CME information and select publications here.
Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.
Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here.
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. CME information and select publications here.
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.
Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.
Clinical investigators discuss available data guiding the management of chronic lymphocytic leukemia. CME information and select publications here.
Dr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. CME information and select publications here.
Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.NCPD information and select publications here.
Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.
Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.
Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. CME information and select publications here.
Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.
Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. CME information and select publications here
Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.
Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.
Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.
Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.
Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma.
Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.
Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.
Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.
Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria.
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma.
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.
Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.
Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.
Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.
Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.
Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.
© 2020-2025 Ivy Podcast Discovery LLC
